Immutep Limited (YP1A) - Total Liabilities
Based on the latest financial reports, Immutep Limited (YP1A) has total liabilities worth €9.86 Million EUR (≈ $11.52 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore YP1A cash generation efficiency to assess how effectively this company generates cash.
Immutep Limited - Total Liabilities Trend (2017–2024)
This chart illustrates how Immutep Limited's total liabilities have evolved over time, based on quarterly financial data. Check YP1A financial resilience to evaluate the company's liquid asset resilience ratio.
Immutep Limited Competitors by Total Liabilities
The table below lists competitors of Immutep Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
Korea | ₩136.13 Billion |
|
ENERGY&MACHINERY KOREA Co.Ltd
KQ:095190
|
Korea | ₩120.55 Billion |
|
Ginar Technology Co Ltd
TWO:6151
|
Taiwan | NT$637.44 Million |
|
Microcosm Technology Co Ltd
TWO:3354
|
Taiwan | NT$133.39 Million |
|
Pesona Metro Holdings Bhd
KLSE:8311
|
Malaysia | RM677.85 Million |
|
S Chand And Company Limited
NSE:SCHAND
|
India | Rs3.16 Billion |
|
Lesico Ltd
TA:LSCO
|
Israel | ILA507.38 Million |
|
AFC Gamma Inc
NASDAQ:AFCG
|
USA | $100.03 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Immutep Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Immutep Limited market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immutep Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immutep Limited (2017–2024)
The table below shows the annual total liabilities of Immutep Limited from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €12.06 Million ≈ $14.10 Million |
+9.82% |
| 2023-06-30 | €10.98 Million ≈ $12.84 Million |
-6.66% |
| 2022-06-30 | €11.76 Million ≈ $13.75 Million |
+34.30% |
| 2021-06-30 | €8.76 Million ≈ $10.24 Million |
-34.13% |
| 2020-06-30 | €13.30 Million ≈ $15.55 Million |
-17.68% |
| 2019-06-30 | €16.15 Million ≈ $18.89 Million |
+19.86% |
| 2018-06-30 | €13.48 Million ≈ $15.76 Million |
+59.84% |
| 2017-06-30 | €8.43 Million ≈ $9.86 Million |
-- |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more